The company provides IT infrastructure services, software development, and maintenance, while also trading in computer hardware and networking equipment for corporate and educational clients.
The company lacks a verifiable moat, as evidenced by an average ROCE of 8.3% which barely covers the cost of capital. While they claim expertise in AI and cloud services, the high revenue CAGR is likely driven by low-margin hardware trading rather than proprietary software with high switching costs or pricing power.
Management has focused on reinvesting in a subsidiary (Moodscope AI) and maintaining a debt-free balance sheet, but the low average ROE of 9.2% suggests that capital is not being deployed into high-return opportunities.
Five years out, the company's aggressive revenue growth proved to be a mirage of low-margin hardware reselling rather than high-value AI intellectual property. The capital tied up in subsidiaries failed to generate a return above the cost of capital, and the abysmal cash conversion ratio eventually led to a liquidity crunch despite the lack of formal debt. As the 'AI' buzzword lost its luster, the market realized the business lacked any proprietary technology, and the significant related-party transactions finally eroded the remaining minority shareholder confidence, leading to a permanent rerating of the stock.
RichFakir rates Shradha AI Technologies Ltd's business quality as poor — 38/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, Shradha AI Technologies Ltd is trading far above our estimate of fair value (expensive on our lens); we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Shradha AI Technologies Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of Shradha AI Technologies Ltd's fair value is about ₹9 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →